Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andreeff

Showing results (491-500 of 506) with videos related to

Pageof 51
Sort By:
Oncotarget|September 8, 2016
Discovery and clinical introduction of first-in-class imipridone ONC201Joshua E Allen, C Leah B Kline, Varun V Prabhu, et al.
Blood Advances|April 1, 2021
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemiaAbhishek Maiti, Courtney D DiNardo, Sa A Wang, et al.
Nature Medicine|April 28, 2022
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapyIrene Ganan-Gomez, Hui Yang, Feiyang Ma, et al.
Haematologica|June 6, 2020
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimensAbhishek Maiti, Caitlin R Rausch, Jorge E Cortes, et al.
Cell Reports|December 30, 2015
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199Juliana M Benito, Laura Godfrey, Kensuke Kojima, et al.
Nature Medicine|March 4, 2022
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapyIrene Ganan-Gomez, Hui Yang, Feiyang Ma, et al.
Leukemia|February 25, 2025
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemiaCourtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, et al.
Leukemia|December 10, 2025
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemiaCourtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, et al.
Blood|March 18, 2015
Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantationUday Popat, Rohtesh S Mehta, Katayoun Rezvani, et al.
Signal Transduction and Targeted Therapy|February 21, 2022
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Pageof 51

Showing results (491-500 of 506) with videos related to

Sort By:
Pageof 51
Oncotarget|September 8, 2016
Discovery and clinical introduction of first-in-class imipridone ONC201Joshua E Allen, C Leah B Kline, Varun V Prabhu, et al.
Blood Advances|April 1, 2021
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemiaAbhishek Maiti, Courtney D DiNardo, Sa A Wang, et al.
Nature Medicine|April 28, 2022
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapyIrene Ganan-Gomez, Hui Yang, Feiyang Ma, et al.
Haematologica|June 6, 2020
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimensAbhishek Maiti, Caitlin R Rausch, Jorge E Cortes, et al.
Cell Reports|December 30, 2015
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199Juliana M Benito, Laura Godfrey, Kensuke Kojima, et al.
Nature Medicine|March 4, 2022
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapyIrene Ganan-Gomez, Hui Yang, Feiyang Ma, et al.
Leukemia|February 25, 2025
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemiaCourtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, et al.
Leukemia|December 10, 2025
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemiaCourtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, et al.
Blood|March 18, 2015
Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantationUday Popat, Rohtesh S Mehta, Katayoun Rezvani, et al.
Signal Transduction and Targeted Therapy|February 21, 2022
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Pageof 51